Document is current
Any future updates will be listed below
-
Authors
Mehta, Rohtesh S. https://orcid.org/0000-0002-8532-544X
Aljawai, Yosra M. https://orcid.org/0000-0002-1649-7651
Kebriaei, Partow https://orcid.org/0000-0002-8607-9404
Rondon, Gabriela
Fingrut, Warren
Smallbone, Portia https://orcid.org/0009-0005-5524-5077
Oran, Betul https://orcid.org/0000-0003-1264-5968
Olson, Amanda https://orcid.org/0000-0002-1669-0355
Champlin, Richard E. https://orcid.org/0000-0002-4314-5037
Shpall, Elizabeth J.
- License Information
-
More Information
Article History
Received: 11 October 2025
Revised: 26 November 2025
Accepted: 12 December 2025
First Online: 12 January 2026
Competing interests
: RSM served as a consultant reviewer for OrcaBio and received honorarium from Lumanity for providing Expert Opinion. EJS serves as a consultant for Cimeio Therapeutics AG, New York Blood Center, Celaid Therapeutics Inc, Scientific Advisor for Adaptimmune Limited, Navan Technologie, Axio Research, FibroBiologics, is on the Board of Directors/Management for National Marrow Donor Program, and License agreement for Affimed, Takeda, Rege Nexus, and is a speaker for Dava Oncology. The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH.
: The study was approved by our Institutional Review Board (2025-0916) which granted a Waiver of HIPAA Authorization for this non-interventional, retrospective research, and adhered to the Declaration of Helsinki.
